We apply the latest science to create, test, and scale solutions to address the most intractable problems in cancer care delivery.
Our Initiatives
We aim to drive high-value cancer care by designing, testing, scaling and evaluating payment models that enhance affordability, access and innovation.
This study, under the Lazarex Foundation IMPACT program, looks at the effect of financial reimbursement on patient enrollment and retention, as well as ethnic/racial diversity, in clinical cancer trials at Abramson Cancer Center.
In this study, we assess the impact of a large commercial payer's utilization management policy on hypofractionated radiation use and associated spending.
The Oncology Care Model (OCM) is Medicare’s first bundled payment program for patients with cancer. We examined baseline characteristics of OCM physician participants and markets with high OCM physician participation to inform generalizability and complement the ongoing practice-level evaluation of the OCM.
Penn Medicine is leveraging its prior experience with the Penn Medicine Independence Blue Cross Radiation Oncology Episode of Care Model (EOC) to innovate payment and improve the quality of care for Medicare beneficiaries.
Our objective is to evaluate the association between a national insurer’s pay-for-performance (P4P) program for oncology and changes in prescribing of evidence-based cancer drugs and spending.